Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
You may also be interested in...
Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo
Libtayo is the first immunotherapy to demonstrate an improvement in OS, PFS and ORR in advanced cervical cancer and approval in this indication could kickstart its lackluster sales to date.
Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.
Sanofi/Regeneron's Libtayo Pivotal Data Shines In Fourth Cancer Type
The Sanofi/Regeneron PD-1 inhibitor Libtayo has become the first immunotherapy to demonstrate an improved overall survival in patients with cervical cancer in a Phase III trial.